Chronic low-dose L-NAME treatment increases nitric oxide production and vasorelaxation in normotensive rats

Physiological Research

Volumn 56, Issue SUPPL. 2, 2007, Pages

  Bernátová, Iveta ^a   Kopincova J ^a   Puzserova A ^a   Janega, P ^a,b   Babal P ^b  

^a INSTITUTE OF CHEMISTRY   (Slovakia)

^b Bratislava   (Slovakia)

Author keywords

Acetylcholine; Blood pressure; Cardiac and vascular structure; Hypertension; Negative feedback regulation; Serotonin

Indexed keywords

ACETYLCHOLINE; ENZYME INHIBITOR; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; SEROTONIN; VASOCONSTRICTOR AGENT; VASODILATOR AGENT;

ANIMAL; AORTA; ARTICLE; BLOOD PRESSURE; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; FEMORAL ARTERY; HEART VENTRICLE; HYPOTHALAMUS; MALE; METABOLISM; ORAL DRUG ADMINISTRATION; RAT; TIME; UPREGULATION; VASODILATATION; WISTAR RAT;

ACETYLCHOLINE; ADMINISTRATION, ORAL; ANIMALS; AORTA; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FEMORAL ARTERY; HEART VENTRICLES; HYPOTHALAMUS; MALE; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; RATS; RATS, WISTAR; SEROTONIN; TIME FACTORS; UP-REGULATION; VASOCONSTRICTOR AGENTS; VASODILATION; VASODILATOR AGENTS;

EID: 38549108048     PISSN: 08628408     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. ARNAL JF, WARIN L, MICHEL JB: Determinants of aortic cyclic guanosine monophosphate in hypertension induced by chronic inhibition of nitric oxide synthase. J Clin Invest 90: 647-652, 1992.
2. BABÁL P, PECHÁŇOVÁ O, BERNÁTOVÁ I, ŠTVRTINA S: Chronic inhibition of NO synthesis produces myocardial fibrosis and arterial media hyperplasia. Histol Histopathol 12: 623-629, 1997.
3. BERNÁTOVÁ I, PECHÁŇOVÁ O, KRISTEK F: Mechanism of structural remodelling of the rat aorta during longterm NG-nitro-L-arginine methyl ester treatment. Jpn J Pharmacol 81: 99-106, 1999a.
4. BERNÁTOVÁ, PECHÁŇOVÁ O, ŠIMKO F: Effect of captopril in L-NAME-induced hypertension on the rat myocardium, aorta, brain and kidney. Exp Physiol 84: 1095-1105, 1999b.
5. BERNÁTOVÁ I, PECHÁŇOVÁ O, PELOUCH V, ŠIMKO F: Regression of chronic L-NAME-treatment-induced left ventricular hypertrophy: effect of captopril. J Mol Cell Cardiol 32: 177-185, 2000.
6. BERNÁTOVÁ I, PECHÁŇOVÁ O, BABÁL P, KYSELÁ S, ŠTVRTINA S, ANDRIANTSITOHAINA R: Wine polyphenols improve cardiovascular remodeling and vascular function in NO-deficient hypertension. Am J Physiol 282: H942-H948, 2002.
7. BREDT DS, SNYDER SH: Isolation of nitric oxide synthetase, a calmodulin-requiring enzyme. Proc Natl Acad Sci USA 87: 682-685, 1990.
8. COHEN GA, HOBBS AJ, FITCH RM, ZINNER MJ, CHAUDHURI G, IGNARRO LJ: Nitric oxide regulates endothelium-dependent vasodilator responses in rabbit hindquarters vascular bed in vivo. Am J Physiol 271: H133-H139, 1996.
9. DABIRE H, CHERQUI C, SAFAR M, SCHMITT H: Haemodynamic aspects and serotonin. Clin Physiol Biochem 8 (Suppl 3): 56-63, 1990.
10. DELACRETAZ E, HAYOZ D, OSTERHELD MC, GENTON CY, BRUNNER HR, WAEBER B: Long-term nitric oxide synthase inhibition and distensibility of carotid artery in intact rats. Hypertension 23: 967-970, 1994.
11. DOLBER PC, SPACH MS: Conventional and confocal fluorescence microscopy of collagen fibers in the heart. J Histochem Cytochem 41: 465-469, 1993.
12. FERREIRA-MELO SE, YUGAR-TOLEDO JC, COELHO OR, DE LUCA IM, TANUS-SANTOS JE, HYSLOP S, IRIGOYEN MC, MORENO H, JR: Sildenafil reduces cardiovascular remodeling associated with hypertensive cardiomyopathy in NOS inhibitor-treated rats. Eur J Pharmacol 542: 141-147, 2006.
13. FIALOVÁ M, DLUGOŠOVÁ K, OKRUHLICOVÁ L, KRISTEK F, MANOACH M, TRIBULOVÁ N: Adaptation of the heart to hypertension is associated with maladaptive gap junction connexin-43 remodelling. Physiol Res 57: in press, 2008.
14. GEROVÁ M, KRISTEK F: Efficiency of NO donors in substituting impaired endogenous NO production: a functional and morphological study. Physiol Res 50: 165-173, 2001.
15. GEROVÁ M, TÖRÖK J, PECHÁŇOVÁ O, MATÚŠKOVÁ J: Rilmenidine prevents blood pressure increase in rats with compromised nitric oxide production. Acta Pharmacol Sin 25: 1640-1646, 2004.
16. GRISCAVAGE JM, HOBBS AJ, IGNARRO LJ: Negative modulation of nitric oxide synthase by nitric oxide and nitroso compounds. Adv Pharmacol 34: 215-234, 1995.
17. GRUMBACH IM, CHEN W, MERTENS SA, HARRISON DG: A negative feedback mechanism involving nitric oxide and nuclear factor kappa-B modulates endothelial nitric oxide synthase transcription. J Mol Cell Cardiol 39: 595-603, 2005.
18. GUIX FX, URIBESALGO I, COMA M, MUNOZ FJ: The physiology and pathophysiology of nitric oxide in the brain. Prog Neurobiol 76: 126-152, 2005.
19. JOVER B, HERIZI A, CASELLAS D, MIMRAN A: Influence of irbesartan and enalapril on changes of renal function associated with the established phase of l-NAME hypertension. J Hypertens 19: 2039-2046, 2001.
20. KRISTEK F, GEROVÁ M, DEVÁT L, VARGA I: Remodelling of septal branch of coronary artery and carotid artery in L-NAME treated rats. Physiol Res 45: 329-333, 1996.
21. KUNEŠ J, HOJNÁ S, KADLECOVÁ M, DOBEŠ OVÁ Z, RAUCHOVÁ H, VOKURKOVÁ M, LOUKOTOVÁ J, PECHÁŇOVÁ O, ZICHA J: Altered balance of vasoactive systems in experimental hypertension: the role of relative NO deficiency. Physiol Res 53 (Suppl 1): S23-S34, 2004.
22. MANDARIM-DE-LACERDA CA, PEREIRA LM: Renal cortical remodelling by NO-synthesis blockers in rats is prevented by angiotensin-converting enzyme inhibitor and calcium channel blocker. J Cell Mol Med 5: 276-283, 2001.
23. OKRUHLICOVÁ L, TRIBULOVÁ N, BERNÁTOVÁ I, PECHÁŇOVÁ O: Induction of angiogenesis in NO-deficient rat heart. Physiol Res 49: 71-76, 2000.
24. PARK SK, LIN HL, MURPHY S: Nitric oxide regulates nitric oxide synthase-2 gene expression by inhibiting NF-kappaB binding to DNA. Biochem J 322: 609-613, 1997.
25. PAULIS L, ZICHA J, KUNEŠ J, HOJNÁ S, KOJŠOVÁ S, PECHÁŇOVÁ O, ŠIMKO F: Regression of L-NAME-induced hypertension: The role of NO-pathway and endothelium-derived constricting factor. J Hypertens 24 (Suppl 4): S7, 2006.
26. PECHÁŇOVÁ O, ŠIMKO F: The role of nitric oxide in the maintenance of vasoactive balance. Physiol Res 56 (Suppl 2): S7-S16, 2007.
27. PECHÁŇOVÁ O, BERNÁTOVÁ I, PELOUCH V, ŠIMKO F: Protein remodelling of the heart in NO-deficient hypertension: the effect of captopril. J Mol Cell Cardiol 29: 3365-3374, 1997.
28. PECHÁŇOVÁ O, BERNÁTOVÁ I, PELOUCH V, BABÁL P: L-NAME-induced protein remodeling and fibrosis in the rat heart. Physiol Res 48: 353-362, 1999.
29. PEREIRA LM, MANDARIM-DE-LACERDA CA: Myocardial microcirculation stereological changes in rats subjected to nitric oxide synthesis inhibition. Pathol Res Pract 195: 177-181, 1999.
30. PÚZSEROVÁ A, CSIZMADIOVÁ Z, ANDRIANTSITOHAINA R, BERNÁTOVÁ I: Vascular effects of red wine polyphenols in chronic stress-exposed Wistar-Kyoto rats. Physiol Res 55 (Suppl 1): S39-S47, 2006a.
31. PÚZSEROVÁ A, KOPINCOVÁ J, CSIZMADIOVÁ Z, BERNÁTOVÁ I: Effect of chronic low dose L-NAME treatment and stress on cardiovascular system of borderline hypertensive rats. Physiol Res 55: 39P, 2006b.
32. RALAY RANAIVO H, DIEBOLT M, ANDRIANTSITOHAINA R: Wine polyphenols induce hypotension, and decrease cardiac reactivity and infarct size in rats: involvement of nitric oxide. Br J Pharmacol 142: 671-678, 2004.
33. RIBEIRO MO, ANTUNES E, DE NUCCI G, LOVISOLO SM, ZATZ R: Chronic inhibition of nitric oxide synthesis. A new model of arterial hypertension. Hypertension 20: 298-303, 1992.
34. ROSSONI G, MANFREDI B, DE GC, V, BERTI M, GUAZZI M, BERTI F: Sildenafil reduces L-NAME-induced severe hypertension and worsening of myocardial ischaemia-reperfusion damage in the rat. Br J Pharmacol 150: 567-576, 2007.
35. ŠIMKO F: Is NO the king? Pathophysiological benefit with uncertain clinical impact. Physiol Res 56 (Suppl 2): S1-S6, 2007.
36. ŠIMKO F, ŠIMKO J: The potential role of nitric oxide in the hypertrophic growth of the left ventricle. Physiol Res 49: 37-46, 2000.
37. ŠIMKO F, MATÚŠKOVÁ J, LUPTÁK I, PINČÍKOVÁ T. KRAJČÍROVIČOVÁ K, ŠTVRTINA S, POMŠÁR J, PELOUCH V, PAULIS L, PECHÁŇOVÁ O: Spironolactone differently influences remodeling of the left ventricle and aorta in L-NAME-induced hypertension. Physiol Res 56 (Suppl 2): S25-S32, 2007a.
38. ŠIMKO F, POTÁČOVÁ A, PELOUCH V, PAULIS L, MATÚŠKOVÁ J, KRAJČÍROVIČOVÁ K, PECHÁŇOVÁ O, ADAMCOVÁ M: Spontaneous, L-arginine-induced and spironolactone induced regression of protein remodeling of the left ventricle in L-NAME-induced hypertension. Physiol Res 56 (Suppl 2): S55-S62, 2007b.
39. TÖRÖK J, KRISTEK F: Beneficial effect of pentaerythrityl tetranitrate on functional and morphological changes in the rat thoracic aorta evoked by long-term nitric oxide synthase inhibition. Vascul Pharmacol 38: 177-182, 2002.
40. TRIBULOVÁ N, OKRUHLICOVÁ L, BERNÁTOVÁ I, PECHÁŇOVÁ O: Chronic disturbances in NO production results in histochemical and subcellular alterations of the rat heart. Physiol Res 49: 77-88, 2000.
41. VAZIRI ND, WANG XQ: cGMP-mediated negative-feedback regulation of endothelial nitric oxide synthase expression by nitric oxide. Hypertension 34: 1237-1241, 1999.
42. VICKROY TW, MALPHURS WL: Inhibition of nitric oxide synthase activity in cerebral cortical synaptosomes by nitric oxide donors: evidence for feedback autoregulation. Neurochem Res 20: 299-304, 1995.